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A group of scientific and public health experts and key stakeholders convened to discuss the state 
of knowledge on the relationship between adjuvanted monovalent inactivated 2009 influenza A 
H1N1 vaccines used during the 2009 influenza pandemic and narcolepsy. There was consensus 
that an increased risk of narcolepsy was consistently observed after Pandemrix (AS03-adjuvanted) 
vaccine, but similar associations following Arepanrix (AS03-adjuvanted) or Focetria (MF59-
adjuvanted) vaccines were not observed. Whether the differences are due to vaccine composition 
or other factors such as the timing of large-scale vaccination programs relative to H1N1pdm09 
wild-type virus circulation in different geographic regions is not clear. The limitations of 
retrospective observational methodologies could also be contributing to some of the differences 
across studies. More basic and epidemiologic research is needed to further elucidate the 
association between adjuvanted influenza vaccine and narcolepsy and its mechanism and to inform 
planning and preparation for vaccination programs in advance of the next influenza pandemic.
Keywords
Narcolepsy; Pandemic influenza; Pandemrix vaccine; Adjuvants; H1N1pdm09 influenza vaccines; 
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1. Objective of meeting
The overall objective of this 2nd International Alliance of Biological Science (IABS) 
meeting was to review the status of the current knowledge regarding the relationship 
between narcolepsy and the administration of the adjuvanted pandemic influenza vaccines, 
especially Pandemrix, with the goal of being prepared for the next influenza pandemic. The 
meeting was organized by IABS in collaboration with the Belgian Federal Agency for 
Medicines and Health Products (FAMHP) and took place in Brussels, Belgium on March 
26–27, 2018. Participants included experts in epidemiology, surveillance, vaccine safety, 
immunology, neurology, and regulatory affairs, as well as representatives from the European 
Centre for Disease Prevention and Control (ECDC), the European Medicines Agency 
(EMA), NIBSC (UK), WHO, CDC, US Food and Drug Administration (FDA), Biomedical 
Advanced Research and Development Authority (BARDA) of the US Department of Health 
and Human Services, GlaxoSmithKline (GSK), IABS, and patient organizations for 
Narcolepsy in Sweden and Ireland.
An initial IABS meeting had been held in Geneva in October 2015 and the results of that 
deliberation have been published [1].
The following questions were addressed during the meeting:
1. What are the latest data on the risk of narcolepsy following exposure to the 2009 
pandemic vaccines?
2. Which scientific data are available and which data are lacking to explain the 
phenomenon seen in 2009–2010?
3. What evidence is there for an association of narcolepsy with wild type influenza 
infection?
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4. What additional work is needed to prepare for the potential use of adjuvanted 
vaccines during a possible future pandemic?
The expected outcomes were: An improved understanding of the relationship between 
narcolepsy and adjuvanted influenza vaccines and preparation for the potential use of 
adjuvanted vaccines if needed during another pandemic.
2. Background
Beginning in Mexico in April 2009, the 2009 H1N1 A/California pandemic influenza strain 
rapidly spread globally [2,3]. As part of a WHO coordinated pandemic response, 
manufacturers developed several monovalent adjuvanted influenza vaccines [4]. Pandemrix, 
a vaccine adjuvanted with Antigen System 03 (AS03), was utilized primarily in Europe and 
approximately 31 million patient doses were administered to populations in Finland, France, 
Germany, Ireland, Norway, Sweden and United Kingdom (ref) [5]. Arepanrix, a similar 
AS03 adjuvanted vaccine, although authorised in the European Union, was primarily utilized 
primarily in Canada, while also Focetria, an MF59 adjuvanted vaccine was utilized in 
Europe, with approximately 6.5 million doses mainly administered to populations in Italy, 
Netherlands and Spain, and globally.
The first official report of a possible increased risk of narcolepsy following receipt of 
Pandemrix vaccine was announced in August 2010 by the Swedish Medical Products 
Agency [6,7]. Soon thereafter, a similar increase was reported by the authorities in Finland 
[8,9]. Both countries offered Pandemrix to more than 50% of their population with 
vaccination coverage in the school-based programs above 60%.
After the initial safety signals, several epidemiological studies were conducted to evaluate 
this association in Europe to ensure that all three adjuvanted vaccines were studied [10–18]. 
To better understand the available epidemiological data and associated laboratory studies a 
meeting was held in Brussels in March 2018 attended by key stakeholders. The objective of 
the meeting was to identify and formulate outstanding research questions that should be 
addressed in further studies in order to prepare for the potential use of adjuvanted pandemic 
vaccines in a future pandemic.
3. The influenza pandemic
Influenza pandemics occur when a new influenza strain evolves and circulates in humans not 
previously exposed to this strain, spreading on a worldwide scale. This frequently leads to 
widespread disease, causing excessive morbidity and mortality. At the onset of a pandemic it 
is not possible to predict the ultimate severity of the outbreak. Faced with a pandemic, the 
public health community, working with vaccine manufacturers, seeks to rapidly produce and 
administer, to as much of the population as possible, vaccines directed against the pandemic 
strain. At the onset of the 2009 H1N1 pandemic several vaccines were rapidly pursued. 
Ultimately, there were eight pandemic vaccines licensed in Europe [19], including three with 
adjuvants to enhance the immune responses and to provide antigen sparing allowing for a 
larger population being vaccinated when vaccine antigen is limited [20]. Unfortunately, due 
to the limitations of influenza vaccine manufacturing techniques, there was a five-month lag 
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period between the identification of the pandemic strain and the availability of the pandemic 
vaccines.2 Thus, wild type H1N1pdm09 circulation preceded vaccine administration in 
many countries, which means that a part of the population had already been infected by wild 
type H1N1pdm09 strain before receiving the pandemic vaccine [21].
As mentioned earlier several adjuvanted vaccines were developed in response to the 
pandemic. Pandemrix, produced by GlaxoSmithKline (GSK) in Dresden, Germany, 
contained the adjuvant AS03, which is a mix of squalene and α-tocopherol [22]. This same 
AS03 adjuvant had been previously included in avian influenza H5 and H7 vaccines where 
its safety and immunogenicity had been tested in adults but with relatively small sample 
sizes [22–24]. When AS03 was included in those avian strain vaccines, it markedly 
enhanced the immune responses and provided dose-sparing (i.e. less antigen needed to 
produce an adequate immune response). Pandemrix was widely distributed in Europe with 
an estimated 30.8 million patient doses administered in line with national procurement 
procedures [5]. In several European countries, including Sweden and Finland, Pandemrix 
was the only pandemic vaccine available for the vaccine campaigns. A similar AS03 
adjuvanted pandemic vaccine, called Arepanrix (ID Biomedical Corp., a subsidiary of GSK 
Biologicals) produced at a manufacturing site in Quebec using a slightly different 
manufacturing process, was licensed for use in Canada [25]. The third adjuvanted vaccine, 
Focetria (Novartis Vaccines and Diagnostics), contained a different squalene based adjuvant, 
MF59, and was used in some countries in Europe in line with national procurement 
procedures, but far fewer doses were distributed, i.e. 6.5 million [26].
The effectiveness of the adjuvanted vaccine in preventing laboratory confirmed influenza 
was reported to be high. In a systematic review and meta-analysis of the effectiveness of the 
2009 pandemic influenza H1N1 vaccines, Lansbury et al. reported pooled adjusted vaccine 
effectiveness against laboratory confirmed H1N1pdm09 infections with adjuvanted and 
unadjuvanted vaccines of 80% (95% confidence interval [CI] 59–90%) and 66% (95% CI 
47–78%), respectively [27]. Overall vaccine effectiveness for the prevention of influenza-
associated hospitalization was 61% (CI 14–82%). Long-term effectiveness of the adjuvanted 
vaccines was found to be approximately 91%, at two years after vaccination [28]. Thus, 
pandemic vaccines were effective in preventing the 2009 pandemic influenza and a long-
term effect was observed up to two years post-vaccination [27].
4. Narcolepsy
Narcolepsy is a rare sleep disorder that is characterized by excessive daytime sleepiness that 
persists life-long. There is also an associated disorder called cataplexy which is the abrupt 
loss of muscle tone in association with emotional situations. The diagnosis of narcolepsy-
cataplexy is confirmed by polysomnography and multiple sleep latency testing (MLST). It 
can also be confirmed with a cerebral spinal fluid determination of a hypocretin 
concentration of < 110 pg/ml. The incidence of the disorder is reported to be 1/100,000 in 
Europeans, however, the diagnosis is often delayed, making precise incidence calculations 
problematic. The peak age at onset is approximately 15 years and the syndrome is highly 
2https://www.cdc.gov/h1n1flu/cdcresponse.htm.
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correlated with presence of the HLA DQB1*0602 haplotype, with over 90% of the subjects 
with narcolepsy-cataplexy having that haplotype [29–31]. Genome wide association studies 
indicate that the cause of the disorder is likely autoimmune in nature [32].
5. Association between narcolepsy and pandemic influenza vaccines or 
influenza infection
With the announcement from the Swedish Medical Products Agency, the Finnish National 
Institute for Health and Welfare assessed their country’s situation and launched a 
retrospective cohort study. That study estimated the relative risk for narcolepsy after 
Pandemrix in children 4–19 years of age at 12.7 (95% CI 6.1–30.8) [13]. In addition, many 
other European countries conducted studies to assess the association between pandemic 
vaccines and narcolepsy, both in children and adults. The results of studies conducted in 
Europe (Finland, Germany, Ireland, England, France, the Netherlands, Norway and Sweden 
[10,12–16,18]) were recently reviewed by Sarkanen et al. who performed meta-analyses of 
their results [33]. During the first year after vaccination, the relative risk of narcolepsy was 
increased 5–14-fold in children and adolescents and 3–8-fold in adults, depending on the 
index date used. Similar elevated risk estimates were found for analyses using onset of 
symptoms as the key index date, with an overall risk of 14.32 (95% CI 8.92–22.99). The 
review concluded that a significantly elevated risk was only associated with Pandemrix [33]. 
The attributable risk for narcolepsy was estimated at 1 additional case per 18,400 doses 
administered in children and adolescents [33]. The risk of narcolepsy was also higher in 
cases with shorter delays between vaccination and onset date. No other pandemic vaccines 
except Pandemrix demonstrated clear associations with narcolepsy [33].
As there was considerable circulation of the pandemic virus in many countries before the 
vaccine was introduced, it was difficult to sort out whether immunized subjects had 
previously been infected with the wild type H1N1pdm09 strain, either asymptomatically or 
symptomatically. This was particularly important to assess in those vaccinated individuals 
who ultimately developed narcolepsy. A study from the Finland National Institute of Health 
and Welfare assessed whether patients who fell ill with narcolepsy after vaccination with 
Pandemrix had specific antibody responses to the non-structural protein 1 (NS1) from the 
H1N1pdm09 virus, which was not a component of Pandemrix vaccine [34]. Using 
quantitative Western blot analysis, only two of the 45 (4.4%) narcoleptic patients vaccinated 
with Pandemrix showed specific antibody responses against the NS1 protein from the 
H1N1pdm09 virus, suggesting that few had previously been infected with the wild type 
H1N1pdm09 virus [34]. In contrast, acute and convalescent sera (14–21 days later) from 
patients who had laboratory confirmed H1N1pdm09 infection, showed high levels of 
H1N1pdm virus NS1-specific antibodies [34]. The study concluded that “it is unlikely that 
H1N1pdm09 virus infection contributed to a sudden increase in the incidence of childhood 
narcolepsy observed in Finland in 2010 after AS03-adjuvanted Pandemrix vaccination”. 
However, the serologic studies were performed on the subjects with narcolepsy two years 
after the pandemic, while the samples on the controls were obtained contemporaneously.
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The hypothesis of the potential impact of a “dual hit” was also raised by meeting 
participants, suggesting that both vaccine administration and wild type 
H1N1pdm09infection in combination could increase the risk of narcolepsy [35]. The 
Norway study also indicated that the combined exposure to influenza and vaccination 
increased the risk ratio for narcolepsy, compared to the exposure of influenza infection alone 
or vaccination alone, suggesting a synergy [16]. However, the role of influenza should be 
viewed with caution due to underreporting of influenza disease. This hypothesis could also 
explain the presence of an association in Finland, Sweden and Norway, where the 
H1N1pdm09 circulation coincided with the vaccination programmes [35].
The SOMNIA study conducted a multi-country study in 13 different study sites located in 
nine countries [36]. This was a retrospective cohort analysis using electronic health 
databases to assess narcolepsy incidence rates before and during H1N1pdm09 virus 
circulation, and after vaccination campaigns in Canada, Denmark, Spain, Sweden, Taiwan, 
the Netherlands, and the United Kingdom. That analysis concluded that there was no overall 
change in incidence rates of narcolepsy after vaccination using any of the adjuvanted 
pandemic vaccines in any of the study sites, except Sweden and Taiwan [36]. In Sweden, 
narcolepsy incidence rate increased significantly after the start of the H1N1pdm09 
vaccination with Pandemrix, particularly in children (incidence rate ratio 9.0; 95% CI 6.9–
11.8) [36]. In Taiwan there was an increased rate of narcolepsy during the circulation of the 
wild type H1N1pdm09 virus in both children and adults prior to the vaccination campaign, 
with incidence rate ratio at 3.4 (95%CI 2.1–5.5) and 2.9 (95%CI 1.6–5.0) in the age groups 
in 5–18 and 19–59 years, respectively, but no increased risk following vaccination with 
Focetria [37]. In Canada there was no overall increased risk of narcolepsy, despite 
widespread use of the AS03-adjuvanted Arepanrix. A case control analysis was also 
conducted in Argentina, Canada, Spain, Switzerland, Taiwan, and the Netherlands, and 
identified 360 cases (150 cases in children and 210 cases in adults) and the analysis did not 
reveal an increased risk of narcolepsy in either children or adults following Arepanrix or 
Focetria [36].
The Taiwan Centers for Disease Control also conducted a case control analysis to investigate 
the relationship between narcolepsy and wild type H1N1pdm09 exposure, using patients 
recruited from sleep centers [37]. They identified 137 narcolepsy cases who met the MSLT 
criteria for narcolepsy (including 64 cases that were HLA DQB1*0602 positive). They 
matched each case to 10 population-based controls and noted a significant risk of narcolepsy 
associated with influenza-like illness in children (p = 0.014). Similar studies conducted in 
China have reported narcolepsy peaking several months after wild type influenza circulation 
with a more pronounced peak in 2010, although laboratory confirmation of influenza 
infection was not performed [38,39].
Two other studies conducted in countries where only non-adjuvanted or MF59-adjuvanted A 
(H1N1) pdm09 vaccines were used, did not detect an association with narcolepsy and 
vaccine administration. One was conducted in the Vaccine Safety Datalink in the United 
States [40] and the other, an ecologic study, conducted in South Korea [11]. However, this 
lack of association may be true or due to the longer lag time in these countries between the 
onset of symptoms and the conduct of the diagnostic MSLT test, often being months to 
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years. In contrast in China and Taiwan, the lag time between symptom onset and diagnosis is 
very short, a few weeks to months. Longer lag times make it more difficult to observe a 
temporal association between vaccine administration and narcolepsy. Partinen et al. have 
also suggested that a shorter lag time is also associated with more severe manifestations such 
as cataplexy which approximately 90% of Pandemrix vaccinated children in Finland were 
reported to exhibit [8]. The onset of narcolepsy appears more explosive in school-age 
children, while cases in adults are diagnosed later or can be more easily missed. These two 
factors might contribute to some of the differences in the observed association across age 
groups and for different time windows between vaccination and disease onset.
6. What is the potential pathogenesis?
An understanding of the pathogenesis of narcolepsy associated with Pandemrix has been 
sought and many important questions have been raised. What actually causes the damage to 
hypocretin-secreting neurons? Is this damage vaccine enhanced, wild type virus related, or is 
it a combination of both vaccine and wild type influenza infection? Is this an autoimmune 
process? What is the level of evidence? What is the significance of the association with a 
specific HLA type? Several speakers discussed this issue and provided insights.
There are no data that pathogenic auto-antibodies in pregnant women with narcolepsy have 
been transmitted to their infants, since all their infants have been born without narcolepsy 
[41]. Some have demonstrated the presence of tissue-specific autoantibodies or activated T-
cells in patients with narcolepsy, but there has been no demonstrated pathogenicity. There is 
a strong relationship between narcolepsy and HLA-DQB1 alleles, but there is evidence that 
the same HLA alleles are also associated with enhanced immune response responsiveness to 
influenza vaccines [42].
The role of wild type virus infection in narcolepsy has also been assessed as a high 
proportion of the vaccinated population was infected by the H1N1pdm09 virus before being 
vaccinated. One study, using results of published and unpublished H1N1pdm09 
seroepidemiological studies, suggested that 47% of children aged 5–19 years of age were 
infected during the pandemic [43]. In Europe, the peak of the pandemic immediately 
preceded or coincided with the mass vaccination program and in Norway, over half of the 
school children were infected before vaccination [44].
It is known that influenza viruses can infect the olfactory receptor neurons and move from 
the olfactory bulb with anterograde axonal transport into the brain. In immunodeficient 
mice, experimental intranasal administration of H1N1pdm09 was shown to infect the lateral 
hypothalamus and the hypocretin-producing neurons [45].
An alternative hypothesis is that after an immune response to a natural H1N1pdm09? 
Infection, CD8 T-cells are generated that can spread to the brain and attack the hypocretin 
neurons that are expressing H1N1pdm09 hemagglutinin [46]. Using a mouse model one 
group demonstrated that CD8 T-cells could destroy neurons in the hypothalamus with this 
loss causing manifestations similar to human narcolepsy [46]. Another group proposed that 
narcolepsy resulted from specific-antigen-associated molecular mimicry coupled with non-
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specific immunostimulation [47]. They reported that antibodies to influenza nucleoprotein 
cross-reacted to human hypocretin receptor 2 and shared motifs between influenza virus 
nucleoprotein and human hypocretin receptor 2. They also demonstrated that sera from 
narcoleptic patients who received Pandemrix had anti-hypocretin receptor 2 antibodies that 
cross-reacted to influenza nucleoprotein.
Another study presented data that autoreactive memory CD4 and CD8 positive T-cells 
specific for self-antigens expressed by hypocretin producing neurons were identified in 
narcolepsy patients and rarely in healthy controls [48]. The autoreactive memory CD4 
response was polyclonal and recognized exogenous peptides but failed to recognize whole 
proteins. Rare autoreactive CD8 T-cell clones were also present in the cerebrospinal fluid of 
the narcoleptic patients. However, they did not identify hypocretin specific T-cells in 
narcolepsy patients.
7. Parental and patient perspective
The patient perspective was presented by representatives of two national narcolepsy 
organizations, one from Ireland and one from Sweden. Patient organizations also have been 
formed in other countries. Narcolepsy has had a major impact on the lives of the affected 
individuals. They require more time to complete their schooling and experience difficulties 
in obtaining and keeping employment, with many only able to work part-time.
A European patient organization, the Pandemrix narcolepsy alliance was formed in 2013 
with patients and their affected families from Finland, Ireland, Norway, Sweden and the UK. 
They have met with the European Commissioners on Health and Consumption in 2014 and 
2016 to discuss opportunities for research support for better treatments and vaccine injury 
compensation systems [49]. Finally, it was noted that vaccine injury compensation systems 
vary significantly among the countries that offered Pandemrix in large vaccination 
campaigns with Finland, France, Norway, Sweden and United Kingdom having a 
compensation system in place while Ireland did not. In Ireland patients or their families had 
to file their claims for compensation in civil court. Several other countries had insufficient 
vaccine injury compensation systems for such a severe injury.
8. Research challenges and proposals for further research
Following a series of presentations on the state of the art of the association between 
development of narcolepsy and Pandemrix vaccination, the meeting participants were 
divided into five working groups to address research challenges and proposals for further 
studies. The groups included; epidemiologic studies, the association of narcolepsy with 
natural wild type influenza infection, the potential mechanisms of pathogenesis, the 
differences between Arepanrix and Pandemrix, and the public health responses needed 
before another pandemic. Each of these will be discussed below.
8.1. Epidemiological studies
Although many large epidemiological studies assessed the risk of narcolepsy associated with 
Pandemrix, there are remaining questions. One question relates to the time windows 
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between pandemic vaccine administration and narcolepsy onset that should be used in 
epidemiological studies. The relative risk for narcolepsy is higher for shorter windows. The 
participants also questioned whether earlier recognition of narcolepsy would result in a spike 
in the incidence, which would be followed by a compensatory drop and a subsequent return 
to baseline incidence. Studies from Finland and England are completed but additional 
studies in Sweden, Norway, Ireland, Germany and Canada could be useful to assess the 
impact of different time windows.
The “dual hit” hypothesis, which suggests that both exposure to natural H1N1pdm09 
infection and to adjuvanted vaccine receipt would have a synergetic effect, should be further 
evaluated using existing sera collected from different populations. Pooling of data and 
conducting additional meta-analyses was debated. It would increase statistical power to 
detect associations, could include non-European countries and allow longer follow-up, but 
would reduce the number of covariates (due to missing data) and would hide the large 
heterogeneities across countries and populations.
Prospective studies collecting sera at different time points during and after the pandemic, 
from various age groups with low vaccine coverage and including subjects with confirmed 
natural influenza infection should be evaluated to determine the kinetics of the decay of NS1 
antibodies. Investment in creating large linked databases would allow for rapid data sharing, 
and real-time monitoring of safety signals. These databases could also provide rapid and 
accurate information on population exposure to a pandemic vaccine by age, risk group and 
product type. Multinational data sharing systems could be used for signal generation and 
algorithms could be developed to identify prespecified conditions of known interest (e.g., 
neurologic conditions such as Guillain-Barré syndrome and narcolepsy). However, since the 
vaccines used in the next pandemic could give rise to other completely unexpected severe 
adverse events (SAEs), artificial intelligence techniques and machine learning could be 
deployed to search databases and identify unique symptom clusters that could herald a new 
adverse event. Such systems could also generate expected rates for various conditions and 
ideally generate real-time vaccine effectiveness estimates to facilitate benefit/risk 
assessments of the vaccines.
Even if such infrastructure was established pre-pandemic with agreed upon protocols for 
multi-country data sharing and ground rules for conducting hypothesis testing studies, high 
quality country-specific studies would still be needed to investigate signals. These studies 
should incorporate local clinicians and epidemiologists who are best placed to understand 
the diagnostic pathways and potential biases and confounders that may be operative in their 
own local and country-level settings. Similarly, while machine learning, and symptom 
algorithms could be useful for signal generation, they would not obviate the need to ensure 
that clinicians are alert to the potential for novel unexpected adverse events and to report 
these promptly to regulatory or licensing authorities. Reporting clinicians should also be 
encouraged to take and store serum samples and potentially cells from cases of suspected 
SAEs to facilitate hypothesis testing if specific problems emerge. While both ECDC and 
EMA performed their own supra-national roles in the last pandemic, there is still room to 
improve collaboration in data sharing between the two entities. Also as a condition of 
licensure, EMA requires manufacturers to conduct their own post marketing safety and 
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effectiveness studies. However, these studies can often only be done by public health 
institutes who have a similar responsibility for the acquisition of safety data. Vaccine 
manufacturers should also work to identify and report adverse events after immunization. 
Improved ways of collaborating between public funded and for-profit organizations should 
be in place before the next pandemic and could use the experience and protocols developed 
by the EU-funded ADVANCE (Accelerated development of vaccine benefit-risk 
collaboration in Europe) project as a model.
8.2. Association between narcolepsy and wild type influenza virus infection
Confirmation of an association of narcolepsy with wild type virus would further our 
understanding of the role of influenza antigens in the causation of narcolepsy and potentially 
impact studies of the mechanism of action of vaccine adjuvants. Several specific questions 
are summarized in Table 1.
8.3. Mechanisms of pathogenesis
Three key aspects were considered in discussing pathogenesis; the vaccine components, the 
wild type virus, and the time window between infection and vaccination. Participants 
proposed future studies including; DQ0602 restricted CD4+ and CD8+ T-cell influenza 
epitopes in in-vitro/ex-vivo analysis, binding of human T-cells to soluble HLA, comparative 
binding of epitopes to DQ002+, DQ0603+ (protective) and non-DQ 602 alleles, and 
screening responses to key influenza antigens (hemagglutinin, neuraminidase, 
nucleoprotein). In addition, responses to multiple seasonal and pandemic influenza viruses 
(H1N1pdm09, H3, H5, H7) and the antibody landscape to various influenza strains (H1 vs 
H3) in individuals with DQ 602+, DQ603 + and non-DQ 602 should be assessed. T-cell and 
antibody responses to H1N1 in patients with narcolepsy compared to controls should also be 
evaluated. Studies could be conducted on the influenza virus by elaborating a regional map 
of the influenza viruses that circulated in China in the geographic area where narcolepsy was 
detected and the tropism of that virus for the olfactory bulb and central nervous system in 
animal models. The time window between infection and vaccination in narcolepsy cases 
needs to be carefully assessed with the potential for ferret or other animal models to be 
pursued. Finally dissecting the differences in the immune-response to influenza infection 
and vaccination with both unadjuvanted and adjuvanted vaccines should be further pursued. 
See summaries in Tables 2 and 4.
8.4. Differences between Pandemrix and Arepanrix
The general consensus of the meeting was that there was an increased risk of narcolepsy 
consistently observed after Pandemrix. However, the risk of narcolepsy after Arepanrix was 
considered from low to none. Only one small study from Quebec suggested an increased risk 
of narcolepsy after Arepanrix [50]. The differences either in the vaccine, in the populations 
in which vaccines were utilized or in the circulation of the wild type virus with respect to the 
timing of vaccination campaigns were considered as likely factors that might explain the 
differences between the two vaccines. These issues are summarized in Table 2.
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8.5. Data needed for informed decision making in the public health response to a 
potential pandemic threat
A successful public health response to an influenza pandemic requires coordinated efforts at 
the international, national, regional, state, and local levels. Furthermore, it requires input and 
coordination among the scientific and medical communities, public health and regulatory 
authorities, elected and appointed government officials, emergency responders, community 
organizations, and the public. A number of public health actions and responses were 
proposed for future pandemics. These are summarized in Table 3.
9. Conclusions and recommendations
The association between the receipt of Pandemrix and the development of narcolepsy has 
been consistent in the countries in which it has been studied. The observed risks differed 
somewhat across settings and the potential reasons for these differences include; individual 
country vaccination policies and vaccination coverage levels, total number of vaccines 
administered to the population, genetics, environmental factors, awareness and detection 
biases, case definitions and case finding. There are no clear associations observed between 
development of narcolepsy and the other pandemic adjuvanted vaccines.
Further epidemiological and fundamental basic research needs to continue and be supported. 
The laboratory studies that should be addressed are summarized in Table 4.
The public health response during a pandemic is critical. Communication needs to be 
enhanced and the medical and public health community need to rely on the lessons learned 
from this pandemic to prepare for the next. Preparedness should go beyond the concerns 
about narcolepsy. In particular:
Epidemiological research requires that international collaboration mechanisms, 
infrastructure, capacity for data sharing and large linked database systems with comparable 
data should be built;
The question of pooling past and future data needs further discussion for agreement; Sharing 
human samples should be explored but must be respectful of confidentiality and informed 
consent issues.
Finally, research on therapeutic options for patients with narcolepsy should be supported and 
clinicians skilled at dealing with narcolepsy should be available to affected patients.
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Table 1
Identified questions that could be addressed in retrospective and prospective epidemiological studies in 
populations with natural influenza infection and/or exposure to adjuvanted pandemic vaccines.
• Is there seasonality in narcolepsy related to influenza and does this exist every year or are there some years that are more prominent than 
others? Are all population equally affected?
• What was the risk window following Pandemrix vaccination for developing narcolepsy and cataplexy, respectively? Any difference observed 
by age groups?
• Could a “dual-hit” with vaccination before or after a natural influenza A H1N1pdm09 infection in European and non-European settings 
explain development of narcolepsy/cataplexy following use of Pandemrix and other adjuvanted pandemic vaccines?
• Could analyses be stratified by different outcomes, exposures and case characteristics, e.g. confirmed diagnosis of narcolepsy, natural H1N1 
infections, different time lags between vaccination and narcolepsy, and age?
• Could a compensatory drop in narcolepsy incidence be observed following the increase in incidence be observed?
• Could associations of vaccine administration or wild type influenza infection be assessed in additional populations/countries/years via case-
control or cohort studies? Were there narcolepsy clusters following the previous pandemics including 1918–1920 with H1N1, in 1957–1958 
with H2N2, and in 1968–1969 with H3N2?
• Could large health care database research be utilized to evaluate retrospective or real-time pandemic vaccine safety and effectiveness by 
vaccine brand during the 2009 pandemic and future pandemics?
• How could studies on vaccine safety and effectiveness involving all stakeholders be facilitated and adequately funded in the next pandemic?
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Table 2
Identified questions that could be addressed in epidemiological studies on the differences between Pandemrix 
and Arepanrix and the association with narcolepsy.
• Is there a difference in the background incidence of narcolepsy between the populations that received Pandemrix and Arepanrix that could 
explain the observed difference in vaccine associated narcolepsy?
• Is there a difference in the expression of the HLA-DQB1*06:02 allele and other HLA types in the populations that received Pandemrix and 
Arepanrix?
• Was there a difference in the time window between vaccination and infection in populations receiving Pandemrix and Arepanrix?
• Could the risk be assessed at the individual level by comparing the risk of narcolepsy according to timing of vaccination relative to infection 
(before, same time, or after) and for each individual calculate recent exposure and interaction of the vaccine effect could be assessed?
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Table 3
Preparedness data needed for informed decision making in the public health response to a potential pandemic 
threat.
• Public health communication plans should be developed in anticipation of future influenza pandemics. Content should include disease 
epidemiology, regulatory processes for licensure, the rationale for age-and risk-based vaccine recommendations, and how vaccine safety and 
effectiveness will be monitored. Information should also be effectively transferred from national and regional levels to local and community 
levels and ultimately to the provider and patient levels.
• Large linked database systems should be built to conduct near real-time active vaccine safety and effectiveness monitoring during a global 
influenza pandemic vaccination campaign.
• Vaccine registries should be established, either within monitoring systems or at the national, regional, or state/provincial levels. There would 
optimally be bidirectional communication capability between registries and the large linked database systems to enhance capture of vaccine 
exposure for safety and effectiveness monitoring.
• Methods, outcomes, and risk and control intervals for adverse events should be standardized and surveillance systems should incorporate 
procedures for rapid chart access and data sharing to evaluate potential safety signals.
• Clinical trials and licensure of adjuvanted pre-pandemic (i.e., pandemic candidate) vaccines should be encouraged in advance of a pandemic. 
These should give consideration to the inclusion of children, the elderly, those with chronic illnesses, pregnant women, and include sufficient 
racial and ethnic minorities to be representative of the general population. It was however recognized that the ethics including vulnerable groups 
in such trials in the absence of a pandemic would require careful consideration.
• Modeling should be used to evaluate the benefit-risk balance when limited data are available.
• The roles, responsibilities, and authority of international, European, national, state/provincial, and local public officials should be clarified in 
advance of a pandemic influenza response and continuously reinforced and communicated to stakeholders and the public during the actual 
pandemic.
• National and when relevant international committees to investigate and promptly review vaccine adverse events of importance should be 
constituted during a pandemi influenza campaign.
• Compensation policies should be developed at the national level in advance of a future pandemic for individuals or parents who believe they or 
their children have suffered an injury from receipt of a recommended pandemic influenza vaccine. The process for developing policies should 
be transparent and preferably would include consideration of wide stakeholder input (public, healthcare providers, public health officials, etc.).
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Table 4
Identified questions that could be addressed in laboratory studies in populations after natural influenza 
infections and/or vaccination with adjuvanted pandemic vaccines.
• What are the kinetics of the decay of NS1 antibodies following a natural influenza infection?
• Is there a difference in the immune response to a natural influenza infection or influenza vaccination in individuals expressing the HLA-
DQB1*06:02 allele compared to other HLA types?
• Is the HLA-DQB1*06:02 allele linked to both vaccine or wild type virus associated narcolepsy?
• Is there a difference in the immune response to an adjuvanted vs a nonadjuvanted influenza vaccination in individuals expressing the HLA-
DQB1*06:02 allele compared to other HLA types?
• Could questions about the HLA relationship be assessed using peripheral blood mononuclear cells (PBMC) stimulated with various pandemic 
strains and measurement of T-cell responses based on HLA status?
• Could bio-banked sera and PBMC from confirmed natural H1N1 infections be analyzed based on HLA status and could new clinical studies 
with PBMC stimulation or antibody measurements following vaccination be assessed based on HLA status?
• What was the role of the different vaccine components for pathogenesis of narcolepsy/cataplexy?
• What differences in the antigen content and related immune response was observed following vaccination with Pandemrix and Arepanrix?
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